Prolonged use may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses
The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes
Intraocular pressure may become elevated in some individuals; if steroid therapy is continued for more than 6 weeks, IOP should be monitored
Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex because of possible corneal perforation; do NOT use in active ocular herpes simplex
Rate of infectious culture positive endophthalmitis is 0.5%; proper aseptic techniques should always be used when administering triamcinolone acetonide
In addition, patients should be monitored following the injection to permit early treatment should an infection occur
Children who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity
Chronic topical corticosteroid therapy may interfere with growth and development in children
Use medium to very high potency for <2 weeks to reduce local and systemic side effects
Use low potency for chronic therapy
Avoid medium to very high potency on face, folds, and groin because can increase steroid absorption
Use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)
Prolonged use may result in bacterial or fungal superinferction; discontinue if dermatological infection persists despite antimicrobial therapy
Discontinue if local sensitization including irritation or redness occurs
Avoid use of high potency steroids in the face